Frontiers in Immunology (Jun 2022)

A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients

  • Peifeng Huang,
  • Qingwei Zuo,
  • Yue Li,
  • Patrick Kwabena Oduro,
  • Fengxian Tan,
  • Yuanyuan Wang,
  • Xiaohui Liu,
  • Jing Li,
  • Qilong Wang,
  • Fei Guo,
  • Yue Li,
  • Long Yang,
  • Long Yang

DOI
https://doi.org/10.3389/fimmu.2022.930673
Journal volume & issue
Vol. 13

Abstract

Read online

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, is one of the fastest-evolving viral diseases that has instigated a worldwide pandemic. Severe inflammatory syndrome and venous thrombosis are commonly noted in COVID-19 patients with severe and critical illness, contributing to the poor prognosis. Interleukin (IL)-6, a major complex inflammatory cytokine, is an independent factor in predicting the severity of COVID-19 disease in patients. IL-6 and tumor necrosis factor (TNF)-α participate in COVID-19-induced cytokine storm, causing endothelial cell damage and upregulation of plasminogen activator inhibitor-1 (PAI-1) levels. In addition, IL-6 and PAI-1 form a vicious cycle of inflammation and thrombosis, which may contribute to the poor prognosis of patients with severe COVID-19. Targeted inhibition of IL-6 and PAI-1 signal transduction appears to improve treatment outcomes in severely and critically ill COVID-19 patients suffering from cytokine storms and venous thrombosis. Motivated by studies highlighting the relationship between inflammatory cytokines and thrombosis in viral immunology, we provide an overview of the immunothrombosis and immunoinflammation vicious loop between IL-6 and PAI-1. Our goal is that understanding this ferocious circle will benefit critically ill patients with COVID-19 worldwide.

Keywords